echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NICE recommends pembrolizumab as an adjuvant therapy for stage 3 melanoma

    NICE recommends pembrolizumab as an adjuvant therapy for stage 3 melanoma

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    NICE has issued guidelines recommending Merck/MSD's Keytruda (pembrolizumab) as a monotherapy for the adjuvant treatment of stage 3 melanoma in adult patients with completely removed lymph nodes


    guide

    Melanoma is the second most common cancer in men and the third most common cancer in women


    diagnosis

    In the past decade, the field of melanoma has made tremendous medical advances, and immunotherapy treatment has become an indispensable part of it


    immunity

    Before adjuvant therapy became an available option for some patients, the standard postoperative practice for melanoma was active surveillance, closely monitoring patients to check for cancer recurrence


    According to the Phase III EORTC1325/KEYNOTE-054 trial on which the approval is based, more than three-quarters of these patients will not have cancer recurrence within one year after initial treatment


    In the overall median follow-up of 42.


    Fig.


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.